Prognostic Value of CTC in HNSCC Patients — CTCHNSCC01  

Recurrence Clinical Trial

Official title: Prognostic Value of Circulating Tumor Cells in Patients With Locally Advanced and Metastatic/Recurrent Head and Neck Cancer

Status Terminated

Clinical Trial Summary

We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.

Clinical Trial Description

1. Histologically or cytopathologically proven head and neck squamous cell carcinoma (HNSCC)

2. Disease status: locally advanced or recurrent/metastasized at initial presentation

3. Age >=20 years old

4. Could understand and signed the informed consents of this study

5. Enrolled patients were classified into three distinct subgroups:

1. Patients underwent curative surgery followed by adjuvant chemoradiotherapy (CRT) because of some pathologic features such as positive margin, pathologic N2, and extracapsular spread (ECS) of involved lymph nodes indicating early relapse according to recommendation from National Comprehensive Cancer Network(NCCN) guidelines;

2. Patients with advanced disease directly underwent definitive concurrent chemoradiotherapy(CCRT);

3. Patients were to have palliative chemotherapy for existence of distant metastasis or poor general condition for definitive CCRT.

6. Blood samples were collected within 7 days before the first dose of chemotherapy. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Death
• Metastasis
• Neoplastic Cells, Circulating
• Recurrence

• NCT number: NCT01884129
• Study type: Observational [Patient Registry]
• Source: Chang Gung Memorial Hospital
• Status: Terminated
• Phase: N/A
• Start date: June 2012
• Completion date: May 2015